In this article, we will look at the 10 Best Penny Stocks to Buy Before They Explode.
Penny stocks tend to attract attention when risk appetite improves, and smaller companies start participating in the market rally. These stocks can move sharply when expectations are low, liquidity improves, or a business shows early signs of an earnings turn. Franklin Templeton says “2026 could be the year that small-caps reassert themselves,” while also noting that “both small-cap quality and value are poised for meaningful rebounds in 2026.” That matters for penny stocks because many of them sit at the speculative end of the small-cap universe.
The broader small-cap backdrop is helping the argument. AllianceBernstein says “Earnings growth, for example, is expected to outstrip those for large companies in 2026” and adds that “small-cap earnings could be widely underestimated by the market.” In summary, the setup is not just about low prices. It is about whether the market has become too pessimistic on smaller companies that may be entering a better earnings cycle. T. Rowe Price makes a similar point, arguing that “the small-cap rebound has not been driven by sentiment alone” because “fundamentals also have turned” and small-cap earnings began to rapidly improve in late 2025.
Against this backdrop, the penny stocks worth watching are not simply the lowest-priced names on the market. The more interesting candidates are those with improving fundamentals, visible catalysts, analyst support, or exposure to themes where investor attention can return quickly. With that in mind, let’s take a look at the 10 Best Penny Stocks to Buy Before They Explode.
Our Methodology
We used the Finviz screener to identify stocks that are trading below $5 per share and offer significant upside from analysts’ price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Playtika Holding Corp. (NASDAQ:PLTK)
On May 7, 2026, Playtika Holding Corp. (NASDAQ:PLTK) reported Q1 EPS of (15c), versus the consensus estimate of 12c. Revenue totaled $744.7M, versus the consensus estimate of $694.65M. CEO Robert Antokol said the company delivered a strong start to 2026, driven by continued momentum in Disney Solitaire and another record quarter for its direct-to-consumer business. Antokol also said management is seeing signs of improving stability across the broader organic portfolio and remains focused on disciplined execution and long-term engagement growth. CFO Tae Lee said first-quarter performance exceeded prior expectations, with SuperPlay tracking ahead of plan and the core portfolio showing strength. Lee added that adjusted EBITDA reflected a planned front-loaded investment cycle tied to the scaling of SuperPlay, which is expected to normalize over the course of the year.
Playtika Holding Corp. (NASDAQ:PLTK) raised its FY26 revenue outlook to $2.75B-$2.85B from $2.7B-$2.8B, versus the consensus estimate of $2.77B.
Last month, Playtika Holding Corp. (NASDAQ:PLTK) announced that a special committee of independent directors is conducting a strategic review of alternatives across the company’s portfolio as part of efforts to enhance shareholder value. The committee retained Morgan Stanley & Co. as financial advisor to evaluate potential opportunities and alternatives, though the company said there is no assurance the process will result in a transaction.
Playtika Holding Corp. (NASDAQ:PLTK), through its subsidiaries, develops mobile games across global markets.
9. Evotec SE (NASDAQ:EVO)
On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated inflammatory skin diseases with significant unmet medical needs. Evotec SE (NASDAQ:EVO) said it will continue supporting the program toward IND submission through its INDiGO platform, which is designed to accelerate the transition from discovery through clinical readiness.
On April 30, 2026, Evotec SE (NASDAQ:EVO) also announced that it received two additional grants from the Gates Foundation for tuberculosis drug discovery and translation programs. The grants follow four earlier TB-related awards from the foundation and total approximately $4.9M over 25 months and $5M over 24 months. The company said the programs are intended to expand the pipeline of tuberculosis drug candidates and advance the most promising combinations toward clinical evaluation while helping reduce development risk.
Earlier in April, H.C. Wainwright assumed coverage on Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target. The firm said the company has been transitioning away from a more asset-heavy integrated structure toward a leaner and more capital-efficient operating model, adding that current share levels appear attractive for long-term investors.
Evotec SE (NASDAQ:EVO) operates as a drug discovery and development company across the United States, Europe, and other international markets.
